medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Number 3

<< Back Next >>

Rev Mex Patol Clin Med Lab 2005; 52 (3)

Tumor markers utility: Ca 15.3 and Ca 27.29 in breast cancer patients

Canché-Chan J, Simón-Domínguez J

Language: Spanish
References: 17
Page: 139-144
PDF size: 144.60 Kb.


ABSTRACT

Objectives: To determine the relationship between the Gen Her2-Neu with the l tumor marker levels of Ca 15.3, and mention the relationship between the gen Her2-Neu with the tumor marker levels of Ca 27.29. Methodology: The tumor markers Ca 15.3 and Ca 27.29 were quantified with automated analyzer AXSYM, with technology of the microparticle enzyme immunoassay. The gen Her2-Neu expression was obtained through immunohistochemistry. The analysis data was measure for descriptive and inferencial statistic. Pearson´s correlation Index was obtained through statistical software SPSS 12.0 for Windows. Results: 697 patients was studied; 24.6% presented breast cancer (n = 138), where 23% was positive for the gen Her2-Neu. Ca 15.3 was elevated in 6.51% more than the Ca 27.29 in the patients with the gen Her2-Neu expression. The Pearson´s correlation index between both tumor markers, it was of 0.978. We can tell that tendency and correlationship is positive and strong for the Ca 15.3 and Ca 27.29. Conclusions: The tumor marker Ca 27.29 don’t offer more advantages with Ca 15.3 due their equivalence. We don´t justified the quantification of Ca 15.3 and Ca 27.29 simultaneously. In patient with positive gen Her2-Neu expression, the tumor marker Ca 15.3 give us a bigger sensibility than Ca 27.29. It is not recommended to use them as method of massive screening.


REFERENCES

  1. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.

  2. Wu JT. Review of circulating tumor markers: From enzyme, carcinoembryonic protein to oncogene and suppressor gene. Ann Clin Lab Sci 1999; 29: 106-111.

  3. Camera A, Villa MR, Rocco S, De-Novellis T, Costantini S, Pezzullo L et al. Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement. Cancer 2000; 88: 75-78.

  4. Hammond ME, Fitzgibbons PL, Compton CC, Grignon DJ, Page DL, Fielding LP et al. College of American Pathologists Conference XXXV: Solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med 2000; 124: 958-965.

  5. Brown FM. Urine cytology. Is it still the gold standard for screening? Urol Clin North Am 2000; 27: 25-37.

  6. Hayes DF. Determination of clinical utility of tumor markers: A tumor marker utility grading system. Recent results. Cancer Res 1998; 15271-85: -85. 72.

  7. Hayes DF, Carney W, Tondini C, Petit D et al. Elevated circulating c-neu oncogene product in patients with breast cancer. Breast Cancer Res Treat 1989; 14: 135a.

  8. Carney W, Hamer P, Petit D et al. Detection and quantitation of the neu oncoprotein. J Tumor Marker Oncol 1991; 6: 53-59.

  9. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer. Breast Cancer Res Treat 1998; 52: 239-46.

  10. Molina R, Jo J, Zanon G et al. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients. Br J Cancer 1996; 74: 1126-1131.

  11. Ruibal A, Colomer R, Genolla J. Prognostic value of CA15.3 serum levels in patients having breast cancer. Horm Metab 1987; 1: 11-15.

  12. Colomer R, Ruibal A, Genolla J et al. Circulating CA15.3 levels in the postsurgical follow-up of breast cancer patients and in nonmalignant diseases. Breast Cancer Res Treat 1989; 13: 123.

  13. Molina R, Zanon G, Filella X y cols. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-47.

  14. American Society of Clinical Oncology (ASCO) Expert Panel. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Report of the ASCO expert panel. J Clin Oncol 1996; 14: 2843-2847.

  15. American Society of Clinical Oncology (ASCO) Expert Panel. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998; 16: 793-797.

  16. Gion M, Mione R, Leon AE, Dittadi R. Comparison of the diagnostic accuracy of CA 27.29 and CA 15.3 in primary breast cancer. Clin Chem 1999; 45: 630-7.

  17. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15: 2322-2328.




2020     |     www.medigraphic.com